x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012313
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro600 of human MTMR3 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MTMR3 |
| UniProt No. | Q13615 |
| Gene ID | 8897 |
| Gene Description | Myotubularin-related proteins are a family of phosphatases with emerging roles in cellular signaling and membrane trafficking. MTMR3, also known as FYVE-DSP1, contains an amino terminal pleckstrin homology domain and a carboxyl terminal FYVE domain. MTMR3 was first reported as a dual-specific phosphatase, having phosphatase activity toward phosphorylated serine, threonine, and tyrosine residues. Subsequent research studies reported that MTMR3 has phosphatase activity toward phosphoinositides, including phosphatadylinositol-3-phosphate and phosphatidylinositol 3, 5-bisphosphate P2). Accumulation of PI3P by the class III phosphoinositide 3-kinase Vps34 is a key element in autophagosome formation. Inhibition of PI3P by MTMR3 can play an important role in suppressing autophagsome formation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
